C. Lord

Molecular Biology · 2005–2019

A researcher in the Science corpus: 10 papers; trusts 9 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 117 citations into it; #10,539 of 17,773 by trust here, #2,053 by citations
• Oncology — 101 citations into it; #826 of 1,698 by trust here, #167 by citations
• Genetics — 50 citations into it
• Cancer Research — 44 citations into it
• Cell Biology — 10 citations into it

Whom C. Lord trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Moynahan
2. Jan H. J. Hoeijmakers
3. N. Turner
4. Michael Weller
5. Alan Ashworth
6. Andrew Tutt
7. M. Jasin
8. Yves Pommier
9. Jonathan A. Ledermann
10. S. Artandi

Who trusts C. Lord overall

1. D. Fruman
2. Alan Ashworth
3. Andrew N. Blackford
4. Honyin Chiu
5. Ruixue Huang
6. T. Niccoli
7. Mark J. O'Connor
8. Guocan Wang
9. J. Prat

Papers from C. Lord's perspective

Ordered by how strongly the researchers C. Lord trusts endorse each paper. Same corpus, a different order for every researcher.

1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (Nature)
2. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (EMBO Molecular Medicine)
3. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks (Cell)
4. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*
5. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. (Journal of Clinical Oncology)
6. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair (Nature Cell Biology)
7. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (The Lancet Oncology)
8. BRCA2 is required for homology-directed repair of chromosomal breaks. (Molecules and Cells)
9. Hallmarks of cancer: the next generation. (Cell)
10. Signatures of mutational processes in human cancer (Nature)

Their papers

• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy (2005) — 6,462 citations
• Resistance to therapy caused by intragenic deletion in BRCA2 (2008) — 1,036 citations
• The DNA damage response and cancer therapy (2012) — 1,734 citations
• BRCAness revisited (2016) — 1,160 citations
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (2009) — 674 citations
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. (2006) — 1,299 citations
• A decade of clinical development of PARP inhibitors in perspective (2019) — 625 citations
• PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017) — 2,440 citations
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer (2015) — 1,991 citations
• Rethinking Ovarian Cancer: Recommendations for Improving Outcomes (2011) — 1,276 citations